Zevalin

Active Ingredient(s): Ibritumomab Tiuxetan
FDA Approved: * February 19, 2002
Pharm Company: * IDEC PHARMACEUTICALS CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zevalin Overview

Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma, a lymphoproliferative disorder. The drug uses the monoclonal mouse IgG1 antibody ibritumomab (pronounced as )[1] in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon bac...

Read more Zevalin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ibritumomab_tiuxetan

Recent Zevalin Forums:

Possible Dosages for this and Related Drugs:

NDC Database Records for Zevalin: (1 result)

Sorted by National Drug Code

• 68152-103 Zevalin Kit by Spectrum Pharmaceuticals, Inc.

Other drugs which contain Ibritumomab Tiuxetan or a similar ingredient: (1 result)

• IBRITUMOMAB TIUXETAN

Related Zevalin Topics: